The effectiveness and cost-effectiveness of screening for and vaccination against hepatitis B virus among migrants in the EU/EEA: A systematic review
Myran, D.T., Morton, R., Biggs, B.-A., Veldhuijzen, I., Castelli, F., Tran, A., Staub, L.P., Agbata, E., Rahman, P., Pareek, M., Noori, T., Pottie, K.
EMCDDA and ECDC join forces to address the challenge of hepatitis
Hepatitis and other drug-related infectious diseases will be the focus of ‘Hepatitis week’, taking place at the EU drugs agency (EMCDDA) in Lisbon from 12–16 June 2017. The initiative will bring together some 100 specialists from: EU Member States, candidate and potential candidate countries to the EU, as well as partner agencies, civil society and professional organisations.
Risk assessment on change of testing requirements for partner donation of reproductive cells
In May 2011, the European Commission asked ECDC to estimate the change in total exposure risk to hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) during reproductive cell handling and storage for secondary parties, if the current scheme of testing at each cell donation would change to testing partner donors of reproductive cells once or twice a year.